The report provides the necessary background information for a firm to operate in the region.

Chapter summaries:
Chapter 1: covers the main characteristics of the Middle Eastern market through a Political, Economic, Social and Technological (PEST) analysis, plus insight into the tax environment and Free-Trade Agreements in place or being negotiated.

Chapter 2: reports on the Intellectual Property Rights environment of each of the countries covered.

Chapter 3: provides a overview of the regional pharmaceutical market, and includes data on consumption, production, imports, exports, as well as market forecasts.

The other chapters are in-depth per-country market studies.

List of Tables
Table 1.1 Regional PEST factors affecting the pharmaceutical industry in the Middle East
Table 2.1 Estimates of intellectual property losses inflicted on PhRMA members, 2004
Table 3.1 Health indicators, 2003
Table 3.2 Pharmaceutical market sizes in the Middle East, 2003
Table 3.3 Annual per capita drug consumption figures in the Middle East, 2001
Table 3.4 Largest local pharmaceutical manufacturers in the Middle East 1
Table 3.5 Competitiveness of Middle Eastern pharmaceutical markets
Table 3.6 Pharmaceutical imports and exports in the Middle East, 2003
Table 4.1 Egypt's healthcare spending
Table 4.2 Egypt's health and government budgets
Table 4.3 Consumer expenditure on health goods and medical services (LEm)
Table 4.4 OTC sales (LEm)
Table 4.5 Egypt's average annual patient co-payment (Egyptian pounds)
Table 4.6 Egypt's top 10 pharmaceutical companies, by revenue, 2001
Table 4.7 Egypt's top 10 pharmaceutical products, by revenue, 2001
Table 4.8 PEST factors affecting Egypt's pharmaceutical industry
Table 5.1 Israel's healthcare expenditure
Table 5.2 Israel's pharmaceutical market, at retail prices
Table 5.3 Israel's consumer expenditure on health goods and medical services
Table 5.4 Israel's pharmaceutical exports and imports
Table 5.5 Israel's non-prescription pharmaceutical market, at retail prices
Table 5.6 Retail sales of OTC healthcare in Israel
Table 5.7 Co-payments for medicines by sick fund in Israel
Table 5.8 Teva's sales and net income
Table 5.9 PEST factors affecting Israel's pharmaceutical industry
Table 6.1 Jordan's health insurance coverage
Table 6.2 Breakdown of Jordan's public health spending
Table 6.3 Jordan's Ministry of Health budgets, 2000-04 (JDm)
Table 6.4 Jordan's health insurance budget, 2000-02 (JDm)
Table 6.5 Admission costs for Jordan's public hospitals
Table 6.6 Dar Al Dawa financials
Table 6.7 PEST factors affecting Jordan's pharmaceutical industry
Table 7.1 Lebanon's pharmaceutical market size and imports
Table 7.2 Co-payments by insurer, in Lebanon
Table 7.3 Hospital co-payments by insurer, in Lebanon
Table 7.4 Lebanon's pharmaceutical production and exports
Table 7.5 PEST factors affecting Lebanon's pharmaceutical industry
Table 8.1 Saudi health-sector statistics, 2003
Table 8.2 Saudi healthcare spending
Table 8.3 Saudi consumer expenditure on health goods and services
Table 8.4 The Saudi private pharmaceutical market
Table 8.5 Saudi pharmaceutical imports (SRm)
Table 8.6 Saudi retail sales of OTC healthcare
Table 8.7 SPIMACO sales and profits, 2003 and 2004
Table 8.8 Tabuk's turnover
Table 8.9 Market share estimates for the Saudi private market, 2005
Table 8.10 Sales estimates for leading products in the Saudi private market, 2005
Table 8.11 Estimates of leading products by units in the Saudi private market, 2005
Table 8.12 PEST factors affecting the Saudi pharmaceutical industry
Table 9.1 Dubai's trade in pharmaceutical products
Table 9.2 Revenue of Drug Control Department by category (in AED)
Table 9.3 Julphar sales and profits
Table 9.4 PEST factors affecting the pharmaceutical industry in the UAE